Faricimab
Faricimab
Faricimab (pronounced: fah-rih-si-mab) is a novel biopharmaceutical drug developed for the treatment of eye diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME).
Etymology
The name "Faricimab" is derived from the combination of the Latin word "fari" meaning to speak, and "cimab", a common suffix used in the naming of monoclonal antibodies. This reflects the drug's function as a signaling molecule in the body's immune response.
Mechanism of Action
Faricimab works by inhibiting two growth factors, vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), which are known to contribute to the progression of AMD and DME. By blocking these factors, Faricimab can reduce abnormal blood vessel growth and leakage, thereby slowing the progression of these diseases.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Biopharmaceutical: A type of drug produced using biotechnology.
- Age-related macular degeneration: A medical condition which may result in blurred or no vision in the center of the visual field.
- Diabetic macular edema: A complication of diabetes caused by fluid accumulation in the macula, or central portion of the eye, that results in blurred vision.
- Vascular endothelial growth factor: A signal protein produced by cells that stimulates the formation of blood vessels.
- Angiopoietin-2: A protein that is involved in the regulation of angiogenesis.
External links
- Medical encyclopedia article on Faricimab
- Wikipedia's article - Faricimab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski